Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities

Journal of Public Health (United Kingdom)

Volumn 38, Issue 1, 2016, Pages 183-188

  Fischer, Benedikt ^a,b,c   Imtiaz, Sameer ^a,d   Rudzinski, Katherine ^a,c   Rehm, Jürgen ^a,c,d,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Attributable fractions; Canada; Cannabis use; Health risks; Morbidity; Mortality; Public health

Indexed keywords

CANADA; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HEALTH CARE PLANNING; HUMAN; LUNG NEOPLASMS; MALE; MARIJUANA ABUSE; MENTAL DISORDERS; MORTALITY; PUBLIC HEALTH SERVICE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TRAFFIC ACCIDENT;

ACCIDENTS, TRAFFIC; CANADA; FEMALE; HEALTH PRIORITIES; HUMANS; LUNG NEOPLASMS; MALE; MARIJUANA ABUSE; MENTAL DISORDERS; PUBLIC HEALTH PRACTICE; RISK FACTORS;

EID: 85007087172     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdv005     Document Type: Article

References (66)

1. Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary of Results for 2012. 2014; http://www.hc-sc. gc.ca/hc-ps/drugs-drogues/stat/-2012/summary-sommaire-eng.php (1 May 2014, date last accessed).
2. Ialomiteanu A, Adlaf EM, Hamilton H et al. 2011 CAMH Monitor EReport: Addiction and Mental Health Indicators Among Ontario Adults 1977-2011. Toronto: Centre for Addiction and Mental Health, 2012.
3. Room R. Legalising a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond. Addiction 2014;109(3):345-51.
4. Caulkins JP. Marijuana Legalization: What Everyone Needs to Know. New York: Oxford University Press, 2012.
5. Room R, Fischer B, Hall W et al. Cannabis Policy: Moving Beyond Stalemate. New York: Oxford University Press, 2010.
6. Lim SS, Aryee M, Laden F et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859): 2224-60.
7. Volkow ND, Baler RD, Compton WM et al. Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219-27.
8. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374(9698):1383-91.
9. Gordon AJ, Conley JW, Gordon JM. Medical consequences of marijuana use: a review of current literature. Curr Psychiatry Rep 2013;15(12):1-11.
10. Popova S, Rehm J, Patra J et al. Illegal drug-attributable morbidity in Canada 2002. Drug Alcohol Rev 2007;26:251-63.
11. Popova S, Rehm J, Patra J. Illegal drug-attributable mortality and potential years of life lost in Canada 2002: implications for prevention and policy. Contemp Drug Probl 2006;33(3):343-66.
12. Pacula RL, Kilmer B, Wagenaar AC et al. Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health 2014;104(6):1021-8.
13. Fischer B, Rehm J, Hall W. Cannabis use in Canada: the need for a 'public health' approach. Can J Public Health 2009;100(2):101-3.
14. Hall W, Degenhardt L. What are the policy implications of the evidence on cannabis and psychosis? Can J Psychiatry 2006;51(9): 566-74.
15. Hall W, Pacula RL. Cannabis Use and Dependence: Public Health and Public Policy. Melbourne: Cambridge University Press, 2003.
16. Fischer B, Jeffries V, Hall W et al. Lower Risk Cannabis use Guidelines for Canada (LRCUG): a narrative review of evidence and recommendations. Can J Public Health 2011;102(5):324-7.
17. Rehm J, Baliunas D, Brochu S et al. The Costs of Substance Abuse in Canada 2002. Ottawa: Canadian Centre on Substance Abuse, 2006.
18. Ezzati M, Lopez AD, Rodgers A et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization, 2004.
19. Rehm J, Taylor B, Patra J et al. Avoidable burden of disease: conceptual and methodological issues in substance abuse epidemiology. Int J Methods Psychiatr Res 2006;15(4):181-91.
20. Walter SD. The estimation and interpretation of attributable risk in health research. Biometrics 1976;32:829-49.
21. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998;88(1):15-9.
22. Beirness DJ, Beasley EE. A roadside survey of alcohol and drug use among drivers in British Columbia. Traffic Inj Prev 2010;11(3):215-21.
23. Beasley EE, Beirness DJ. Alcohol and Drug Use Among Drivers Following the Introduction of Immediate Roadside Prohibitions in British Columbia: Findings From the 2012 Roadside Survey. Ottawa: Beirness & Associates, Inc., 2012.
24. Ramaekers JG, Berghaus G, van Laar M et al. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004;73(2):109-19.
25. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.
26. Li M, Brady JE, Di Maggio CJ et al. Marijuana use and motor vehicle crashes. Epidemiol Rev 2012;34(1):65-72.
27. Asbridge M, Mann R, Cusimano MD et al. Cannabis and traffic collision risk: findings from a case-crossover study of injured drivers presenting to emergency departments. Int J Public Health 2014;59(2): 395-404.
28. Brubacher JR, Chan H, Martz W et al. Recent drug use in injured British Columbia drivers. In: Presented at the Canadian Multidisciplinary Road Safety Conference, Vancouver, BC, 2014.
29. Brubacher JR. Cannabis and motor vehicle crashes. BCMJ 2011;53(6):292-3.
30. Pitel S, Solomon R. Estimating the Number and Cost of Impairment-Related Traffic Crashes in Canada: 1999 to 2009. Oakville: MADD Canada, 2012.
31. Transport Canada. Canadian Motor Vehicle Traffic Collision Statistics, 2011. Ottawa: Public Works and Government Services Canada, 2013.
32. Asbridge M, Mann R, Cusimano MD et al. Cycling-related crash risk and the role of cannabis and alcohol: a case-crossover study. Prev Med 2014;66:80-6.
33. Nordstrom BR, Levin FR. Treatment of cannabis use disorder: a review of the literature. Am J Addict 2007;16(5):331-42.
34. Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry 2009;21(2):96-103.
35. Anthony J. The epidemiology of cannabis dependence. In: Roffman R, Stephens R (eds). Cannabis Dependence: It's Nature, Consequences and Treatment. Cambridge, UK: Cambridge University Press, 2006.
36. Lev-Ran S, Imtiaz S, Rehm J et al. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). Am J Addict 2013;22(2):93-8.
37. Pearson C, Janz T, Ali J. Health at a Glance: Mental and Substance Use Disorders in Canada. Ottawa: Minister of Industry, 2013.
38. Drug and Alcohol Treatment Information System (DATIS). Substance Abuse Statistical Tables: Fiscal Year 2007/2008 to Fiscal Year 2012/2013. Toronto: Centre for Addiction and Mental Health, 2013.
39. Grant BF, Stinson FS, Dawson DA et al. Prevalence and cooccurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-16.
40. Jane-Llopis E, Matytsina I. Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev 2006;25(6):515-36.
41. Rehm J, Room R, Monteiro M et al. Alcohol use. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL (eds). Comparative Quantification of Health Risks. Global and Regional Burden of Disease Attributable to Selected Major Risk Factors, Vol. 1. Geneva: World Health Organization, 2004, 959-1108.
42. Rehm J, Baliunas D, Borges GLG et al. The relation between different dimensions of alcohol consumption and burden of disease-an overview. Addiction 2010;105(5):817-43.
43. Moore THM, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370(9584):319-28.
44. Zammit S, Moore THM, Lingford-Hughes A et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008;193(5):357-63.
45. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009;259(7):413-31.
46. Degenhardt L, Hall WD, Lynskey M et al. Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med 2009;6(9):e1000133.
47. Peto R, Boreham J, Lopez AD et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992;339(8804):1268-78.
48. Dealberto M. Are the rates of schizophrenia unusually high in Canada? A comparison of Canadian and international data. Psychiatry Res 2013;209(3):259-65.
49. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto: Canadian Cancer Society, 2014.
50. Mehra R, Moore BA, Crothers K et al. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 2006;166(13):1359-67.
51. Hashibe M, Straif K, Tashkin DP et al. Epidemiologic review of marijuana use and cancer risk: a systematic review. Alcohol 2005;35(3):265-75.
52. Berthiller J, Bartal M, Ayed FB et al. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 2008;3(12):1398-403.
53. Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 2013; 24(10):1811-20.
54. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer 2007;110(7):1429-35.
55. Hall W, MacPhee D. Cannabis use and cancer. Addiction 2002; 97(3):243-7.
56. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379(9810):55-70.
57. Degenhardt L, Whiteford HA, Vos T et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One 2013;8(10):e76635.
58. Calabria B, Degenhardt L, Hall Wet al. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 2010; 29(3):318-30.
59. Schizophrenia Society of Canada. Cannabis & Psychosis: Exploring the link. 2011; http://cannabisandpsychosis.ca/ (1 October 2014, date last accessed).
60. Cole K. Canadian study links cannabis and psychosis in youth. 2013; http://www.madinamerica.com/2013/12/canadian-study-linkscannabis- psychosis/ (1 October 2014, date last accessed).
61. CBC News. Information/facts about marijuana use and mental illness. 2013; http://www.cbc.ca/natureofthings/features/information-factsabout- marijuana-use-mental-illness (1 October 2014, date last accessed).
62. Canadian Centre on Substance Abuse. Clearing the smoke on cannabis series: highlights. 2014; http://www.ccsa.ca/Resource%20Library/ CCSA-Clearing-Smoke-on-Cannabis-Highlights-2013-en.pdf (1 October 2014, date last accessed).
63. Freeman J, Watling C, Davey J et al. Perceptual deterrence versus current behaviours: a study into factors influencing drug driving in Queensland. Road Trans Res 2010;19(3):3-13.
64. Du Pont RL, Voas RB, Walsh JM et al. The need for drugged driving per se laws: a commentary. Traffic Inj Prev 2012;13(1):31-42.
65. McRae A, Budney A, Brady K. Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat 2003;24(4):369-76.
66. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend 2005; 80(2):147-59.